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Basal and stimulated rates of renal secretion and excretion of
prostaglandins E2, F,,, and 13,14-dihydro-15-keto F,, in the dog.
Using sensitive radioimmunoassays for POE2, POF,, (POE,,, and
POP,,,), and 13,l4dihydro-15-keto POP,, (DHKP2,, + kJ, we have
accessed basal and stimulated rates of secretion and excretion of
these prostaglandins in the dog. Basal secretory rates were calcu-
lated from renal veno-arterial differences and renal blood flow,
whereas excretory rates were calculated from urinary measure-
ments. Basal secretory rates of POE2 and POP, were 29 5 and
103 34 pg/g of kidney/mm (40 measurements in 17 dogs); there
were no consistent veno-arterial gradients for DHKF,. Arterial
concentrations of POE2 and POP, were 14 1.6 and 34 2.6 pg/
ml; renal venous concentrations were 23 2.1 and 65 10 pg/mI,
N = 40. Twelve-minute constriction of the renal artery (N = 6)
with 50% reduction in RBP increased the secretion of POE2 and
POF, twofold to fourfold (P <0.025). There was a good correla-
tion between the recovery of RBP during constriction and the
magnitude of the increase of prostaglandins. Renal arterial infusion
of angiotensin II (N = 6) at 50 ng/min decreased REF 25% and
increased (twofold) the release of both POE2 and POF,, (P <
0.025). Renal arterial infusion of bradykinin (N = 5) at 2 1Lg/min
increased RBF 70% and stimulated the secretion of both POE0 and
POF, at least tenfold. Urinary excretion of PGF,,, POE2, and
DHKF, increased simultaneously after bradykinin and angiotensin
II. We conclude that ischemia, angiotensin II, and bradykinin
stimulate prostaglandin synthesis by increasing the availability of
arachidonic acid as substrate for prostaglandin synthesis. Our data
indicate that the renal production of POE2 and POP0, are tightly
linked, since none of the tested stimuli selectively increased either
class of prostaglandin. The measurement of the urine metabolite,
DHKF,, offered no advantages over measurement of the primary
prostaglandins in these acute studies.
Déhits hasanx et stimulés de secretion et sl'excrétion rénales de
prostaglandines E2, F,, et 13,14-dihydro-1S-ceto-F, chez Ic chien.
A l'aide de dosages radioimmunologiques sensibles de POE2,
POP0, (POF2,, et POP,,) et de 13,14-dihydro-iS-ceto POP,
(DHKPa, et , nous avons evalué les debits de secretion et
d'excretion basaux et stimules de ces prostaglandines chez le
chien. Les debits de secretion basaux ont été calculés a partir de Ia
difference veino-artérielle rénale et du debit sanguin renal alors
que les debits d'excrétion ont été obtenus a partir des determina-
tions urinaires. Let debits basaux de secretion de POE2 et POP,
sont de 29 5 et 103 34 pg/g de rein/mm (40 determinations chez
17 chiens); il n'y a pas de gradient veino-artériel appreciable pour
DHKF,,. Les concentrations artérielles de POE2 et POP, sont de
14 1,6 et 34 2,6 pg/mI; les concentrations veineuses rénales
sont de 23 2,1 et 65 10 pg/mI, N = 40. Douze minutes de
constriction de l'artère rénale (N = 6) avec reduction de moitié du
debit sanguin renal augmentent Ia secretion de POE2 et de POP,,
d'un facteur 2 a 4 (P <0,025). II y a une bonne correlation entre le
retour a la normale du debit sanguin renal après constriction et
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l'importance de l'augmentation des prostaglandines. La perfusion
d'angiotensine II dans l'artère renale (N = 6) a 50 ng/min diminue
le debit sanguin renal de 25% et double Ia liberation de POE2 et de
POP (P < 0,025). La perfusion de bradykinine dans l'artére renale(N = 5) 2 sg/min augmente le debit sanguin renal de 70% et
stimule Ia secretion de POE, et de POP, au moms 10 fois.
L'excrétion urinaire de POP,,, POE,, et DHKP, augmente simul-
tanément après bradykinine et angiotensine II. Nous concluons
que l'ischémie, l'angiotensine II et Ia bradykinine stimulent la
synthCse de prostaglandine en augmentant Ia disponibilité de
l'acide arachidonique, substrat de cette synthese. Nous resultats
indiquent que les productions renales de POE2 et POP, sont
etroitement liees puisqu'aucun des stimuli utilisés ne peut faire
augmenter de façon selective une classe de prostaglandines. La
determination du metabolite urinaire, DFIKP,, n'a pas de super-
iorité par rapport a Ia determination des prostaglandines primaires
dans ces etudes aigues.
Although renal prostaglandin synthesis has been
studied in many species (dog, rat, rabbit, and man)
uncertainties remain about the extent of the basal
rate of in vivo production and the participation of
PGF20, as well as PGE2 in the renal response to
various stimuli [1—41. The problems associated with
the measurement of basal secretory rates are com-
pounded by the frequent use of laparotomy to pre-
pare animals for study with subsequent elevation of
prostaglandin production [51. Although anesthesia
generally does not stimulate renal synthesis of pros-
taglandins, extensive surgical manipulation via lapa-
rotomy does enhance renal venous levels of PGE
[5]. Furthermore, accurate assessment of renal pro-
duction of prostaglandins necessitates measurement
of arterial as well as venous levels since arterial
concentrations may not be negligible.
Presently there is general agreement that renal
production of PGE2 is enhanced by renal arterial
constriction [6—7] by infusion of vasoconstrictors
such as angiotensin II or norepinephrine [8—12] and
by the vasodilator bradykinin [13—161. Most of these
studies have employed the superfused organ bio-
assay system (either "on line" or after concentrative
extraction of large volumes of blood), which is able
to detect PGE2 more accurately than PGF20,. Except
0085—2538/78/0013—0136 $01.60
© 1978, by the International Society of Nephrology.
Renal prostaglandins secretion and excretion 137
for the report by McGiff et al of an increase of PGE2
and PGF2-like substances measured by bioassay
after renal ischemia in the dog [61, other authors
have not found increments of PGF2, after ischemia
[17], angiotensin II infusion, [8—11] or bradykinin
infusion [131; or PGF2 was simply not measured
[16, 18].
It has been suggested that a metabolite of PGF2,
namely 13,1 4-dihydro- 1 5-keto-PGF2, (DH KF), was
a conveniently measured end-product whose con-
centration should reflect the turnover of PGF2a [19,
20]. Since DHKF as well as PGE2 and PGF2 are
excreted into the urine, excretory rates of these sub-
stances should parallel renal synthetic rates. These
observations could have important ramifications,
since it is far easier to obtain urine samples than
renal arterial and venous plasma.
The objectives of the present study were 1) to
measure "basal" secretory rates of PGE2, PGF,
and DHKF with sensitive radioimmunoassays in
the anesthetized dog, using a retroperitoneal, flank
approach to the kidney; 2) to assess the responses of
renal secretion of PGFa as well as PGE2 to renal
ischemia, angiotensin II infusion, and bradykinin
infusion; and 3) to evaluate the use of urine excreto-
ry rates of PGE2, PGFa, and DHKF,, as a measure of
renal prostaglandin production.
Methods
Animal preparation. Twenty mongral dogs of
either sex were used. Their weights ranged from 18
to 30 kg, with an average weight of 23 kg. The
animals were anesthetized with pentobarbital (30 mg/
kg, i.v.) without endotracheal intubation. A flank
incision with retroperitoneal dissection was always
used to isolate the renal vessels. The left side was
preferred, but if a double renal artery was found, the
right kidney was exposed. Tygon catheters were
placed in the aorta by retrograde passage via the
femoral artery up to the level of the renal arteries. A
nonocciusive catheter was directly inserted into the
left renal vein, and the renal artery was cannulated
with either a nonocclusive catheter or a 25-gauge
needle for the arterial infusions. All catheters were
filled with heparin solutions between blood sam-
plings. An electromagnetic flow probe (Statham) was
placed around the renal artery. For the experiments
of arterial constriction, an hydraulic occlusion cuff
was placed distal to the flow probe. In some experi-
ments, the left ureter was cannulated directly mid-
way between the kidney and the bladder.
Experimental protocols. After completion of the
preparative surgery, we allowed 60—120 mm for sta-
bilization of renal blood flow (RBF). Blood pressure
(BP), mean RBF, and phasic RBF were continuously
monitored. In the constriction experiments, the cuff
was inflated to produce 50% initial reduction in RBF.
The constriction was maintained for 12 mm, and
renal venous samples were taken at 3, 6, 9, and 12
mm during ischemia and at 5, 10, 20, and 40 mm after
release of the occlusion. In the angiotensin experi-
ments, we infused angiotensin II into the left renal
artery at 10 ng/min and 50 nglmin for 15 mm each,
and samples of renal venous blood were taken at 5,
10, and 15 mm of the infusion. Bradykinin was
infused into the renal artery at 2 j.g/min for 15 to 20
mm, and two renal venous samples were taken at
variable times. In all experiments, two control sam-
pies of renal vein blood were always obtained prior
to constriction or infusion of the angiotensin or
bradykinin. Aortic blood was sampled during each
period, and we assumed that aortic prostaglandin
concentrations were identical with renal arterial
values.
Aortic and renal venous blood samples of 5 ml
were drawn into plastic syringes containing 14 mg of
EDTA, 250kg of aspirin, and 5 mg of sodium azide.
The blood was drawn slowly over 30 to 60 sec to
avoid hemolysis and any platelet damage which
could increase PGE2 and PGFa concentrations in the
plasma. The 5-mi whole blood samples were immedi-
ately iced and centrifuged within 15 mm. The plasma
was frozen and assayed within 14 days. Urine sam-
ples were centrifuged and frozen without pre-
servatives.
Radioimmunoassay. The techniques of sample
extraction, silicic acid column chromatography, and
radioimmunoassay for PGE2 and PGF,, have been
published previously for the plasma, and the same
procedure was used for urine [21]. We also assayed
PGE2, using an iodinated derivative of PGE2 (1251) as
well as with the conventional 3H derivative [22]. We
measured DHKFa with a recently described assay
employing iodinated tracers [23]. The correlation
between the values of PGE2 determined by the 3H
and the 1251 techniques was excellent as demonstrat-
ed by a regression coefficient of 0.889 in 167 samples
(P < 0.001). Therefore, we used the mean value of
both methods. The sensitivities of these radioimmu-
noassays, determined by the amount of unlabelled
prostaglandin required to displace 50% of the iso-
topic pro staglandin from the specific antibody were
as follows: 3H-PGE2, 7.3 0.3 pg; 1251-PGE2, 1.6
0.2 pg; 3H-PGF2, 22.6 3.3 pg; '25I-DHKF2, 10.4
1.1 pg; N = 19, 11, 19 and 7, respectively. Recov-
eries of labelled PGE2 and PGF2a added to original
plasma were 79.9 1.9% and 80.7 1.6%, N = 100,
respectively. Since the antiserum for PGF2 and
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DHKF2. does not discriminate between la and 2a
compounds [21, 231, our results are reported as
PGFa and DHKFCX to denote total PGF and DHKF.
Since the antiserum to POE2 clearly differentiates
between POE2 and POE1 121], our data are reported
as POE2. All values were corrected for the measured
recovery of the tracer pro staglandin.
Chemicals. We obtained the following chemicals
from the sources indicated in parentheses: angioten-
sin II (Ciba-Geigy), bradykinin (Sandoz), indometha-
cm (Merck Sharp & Dohme), meclofenamate (Parke
Davis), unlabelled prostaglandin (Upjohn), tritiated
POE2 and POF2a (New England Nuclear), and iodi-
nated POE2 and iodinated DHKF were prepared in
our laboratory [22, 23].
Statistical methods. Standard statistical tech-
niques were used for determination of mean values,
variation, and correlation coefficients. Unless noted
otherwise, we used nonparametric paired analyses of
the data, namely Wilcoxon's signed rank test since
the data were not distributed in a Gaussian pattern.
Results
Basal secretory rates of prostaglandins. Table I
summarizes our results for the determinations of the
basal aortic and renal venous concentrations and the
renal secretory rates for POE2, POF0 and DHKF0 ill
17 pentobarbital-anesthetized dogs. The secretory
rate was derived by the following calculation: Secre-
tory rate (pglg of kidney/mm) = [venous concentra-
tion (pg/ml) — arterial concentration (pglml) x renal
100—Hctblood flow (mI/mm) X
100 renal weight
(g)].
There was no veno-arterial difference in 6 of 34
measurements of POE2 and in 8 of 33 measurements
of POFa. These data were considered as "zero secre-
tory rate." The basal F!E secretory ratio was varia-
ble, ranging from 1.2 to 7.1 with a mean value of 3.5.
There were no differences between the arterial and
PGE, PUFLY DHKFI
Aorta, pg/mi 14 1.6
(39)
34 2.6
(32)
65 5
(15)
Renal vein, pg/mi 23 2.1"
(41)
65 10d
(41)
56 5
(16)
Secretory rate, 29 5 103 34 —
pg/g kidney/mm (34) (33)
venous concentrations of DHKF, and hence, no
basal secretory rate could be calculated. These cal-
culations underestimate the total renal secretion or
production rate of prostaglandins since excretion
into the urine and degradation within the kidney also
occur (see Discussion). There was no correlation
between the control renal blood flow and the mea-
sured basal secretory rates of either POE2 or POF0.
Renal arterial constriction (Fig. l and Table 2).
The renal artery was constricted for 12 mm in 6 dogs.
Renal blood flow fell from 306 50 mI/mm to 168
20 ml/min. Prostaglandin secretory rates were deter-
mined every 3 mm during the constriction and at 5,
10, 20 and 40 mm during the recovery. Table 2
contains the data for each of the 4 points in time after
constriction and during recovery, whereas Figure 1
depicts the mean of all measurements during each
period. Renal secretion of POE2 increased twofold
. 1001
Uno 00
control constriction Recovery
Fig. 1. Renal artery constriction. The values shown are the mean
5EM of the responses of renal blood flow (RBF), and renal
secretion of POE2 and POE,, before, during, and after a 12-mm
constriction of the renal artery. N no. of measurements. The
values for prostaglandin secretion are expressed in pg per g of
kidney per miii. Six dogs were used; however, the data during
constriction were collected every 3 mm and during recovery at 5,
10, 20 and 40 mm. All individual data points (see Table 2) for the
constriction period and recovery period were combined in order to
represent the total response for each period. Asterisks = P <
0.025, compared to control using Wilcoxon's rank sum test.
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Table 1. Renal production of prostaglandins under basal
conditionsa
Values are the mean 5EM. Parentheses contain the number
of determinations in 17 dogs (POE2 and POE,,).
1 13, 14-dihydro-l5-keto POF,,.
P < 0.005 compared to arterial value (paired t test).
P < 0.025 compared to arterial value (paired t test).
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Table 2. Renal blood flow and renal secretion of PGE2 andPGF after renal arterial constrictiona
Fig. 2. The relation between the increment qfPGE2 secretion and
changes of renal blood flow after renal arterial constriction or
infusion ofangiotensin Ii. These data were obtained in the experi-
ments shown in Figs. 1 and 3. The values for RBF were calculated
as the differences of RBF immediately prior to release of the
constriction (12 mm) or cessation of the angiotensin infusion (15
mm) and of RBF at its nadir after onset of constriction or infusion.
during the constriction and almost fourfold after
release of the constriction. We did not observe an
increase of PGFn secretion during the constriction,
but during the recovery there was a substantial incre-
ment of PGF0 release. Three dogs had good recovery
of RBF after the onset of the constriction (incre-
ments of 70 to 145 mllmin); these same animals had
the largest increase of PGE2 release (3- to 10-fold)
during constriction. Figure 2 summarizes the relation
between PGEZ secretion and the recovery of RBF.
F/E secretory ratios varied from 1.7 to 3.9 (mean,
2.6) during constriction and increased during recov-
ery to a range of 2.9 to 5.9 (mean, 4.3). Arterial BP
(systemic) was 148 8, 143 9, and 139 8 mm Hg
(mean SEM) during control arterial constriction
and recovery periods, respectively.
Angiotensin 11 infusions (Fig. 3 and Table 3). We
infused angiotensin II into the renal artery in doses of
10 and 50 ng/min over 15 mm in 6 dogs. Systemic
arterial BP was 138 9, 140 12, and 138 11 mm
Hg (mean SEM) during control, angiotensin II
0
100 *
Fig. 3. Renal arterial infusion of angiotensin II. Angiotensin II
was infused at 10 ng/min and 50 ng/min for 15 mm, and prostaglan-
din secretion was measured at 5-mm intervals in 6 dogs. All
individual measurements during each infusion of angiotensin have
been grouped (see Table 3). Asterisks = P < 0.025 with Wilcox-
on's rank sum test. Values are the mean SEM. N = no. of
measurements.
infusion, and recovery periods. Figure 3 and Table 3
summarize the results. Table 3 contains the results at
5, 10, and 15-mm intervals during angiotensin infu-
sion, and Figure 3 depicts the mean data of all mea-
surements during angiotensin infusion. At an infu-
sion rate of 10 ng/min, there was no change of RBF,
and the secretory rates of PGE2 and PGF, were only
slightly augmented. When the infusion rate was 50
ng/min, RB F decreased from 317 45 mllmin to 250
40 mI/mm; concomitantly, the secretion of PGEZ
increased twofold, and PGF. increased fourfold.
During the recovery period, 20 mm after cessation of
the infusion, RBF and PGE2 secretion rates were
comparable to control values, whereas PGF€, secre-
tion, although falling, remained elevated. It was gen-
erally true that RBF decreased less in response to
angiotensin II in those dogs which increased prosta-
glandin production the greatest. Figure 2 shows the
relationship between the decrement of RBF after
angiotensin II infusion and the extent of PGE2 secre-
tion. The secretory ratios of FIE appeared to
Control
Constriction Recovery
3 mm 6 mm 9 mm 12 mm 5 mm 10 mm 20 mm 40 mm
RBF, ml/min 306 51 161 33 168 42 178 46 164 50 283 40 308 50 307 48 330 71
PGE2, pglglmin 22 12 37 9 43 14 44 18 70 19 87 38 65 20 70 36 86 37
PGF, pg/glmin 157 88 87 48 93 47 127 57 117 31 252 114 385 258 300 179 361 202
=0
g
Data are presented as the mean SEM of experiments.
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Table 3. Renal blood 110w and renal secretion of PGE2 and PGFa after infusion of angiotensin 1P
Control
Angiotensin
Recovery5 mm 10 mm 15 mm
RBF, mI/info 317 45 261 50 271 45 253 44 294 63
POE2, pg/glmin 45 12 87 25 84 10 55 15 50 15
PGFa, pg/g/min 45 16 163 63 200 122 216 121 125 64
a Data are presented as the mean SEM for 6 experiments.
Angiotensin II was infused into the renal artery at 50 nglmin.
0
g
0
a-
Control Bradykinin Recovery
Fig. 4. Renal arterial infusion of bradykinin. Bradykinin (2/Lg per
mm) for 15 mm was given to 5 dogs, and prostaglandin secretion
was determined twice during the infusion. Asterisks = P < 0.025
with Wilcoxon's rank sum test. Values are the mean SOM. N =
no. of measurements.
increase during angiotensin II infusion (50 ng/min) to
a range of 1.9 to 3.9 from rather low control values of
1.2 to 1.8.
Bradykinin infusion (Fig. 4). Bradykinin was
infused at a dose of 2xg!min into the renal artery of 5
dogs. Bradykinin produced an immediate increase of
RBF which was maintained for 3 to 5 mm and then
slowly and progressively decreased. The pattern of
prostaglandiri secretion was similar with a very rapid
increase, as early as 3 mm, and with a slow decre-
ment as the infusion continued. In every instance the
second measurement of POE2 and PGF0 secretion in
each experiment was lower than the first measure-
ment. RBF increased from a control value of 257
47 to 422 68 after 3 to 10 mm of bradykinin infusion
and to 381 98 mI/mm prior to cessation of the
bradykinin infusion. Systemic arterial BP was 133
13 mm Hg during the control period and 131 12
mm Hg during the bradykinin infusion. The secretion
of POEZ increased from a control value of 21 5 to
467 200 and to 183 67 pg!g!min after 3 to 10 mm
and 8 to 15 mm, respectively, of bradykinin infusion.
The comparable secretory rates of PGF0 were 35
17 during the control and 505 91 and 261 72 pglgl
mm during bradykinin infusion. Figure 4 illustrates
the mean data from each period. The secretory ratio
of F/E did not change during the infusion.
Inhibitors of prostaglandin synthesis. We evaluat-
ed the effects of indomethacin (2 to 3 mg/kg of body
wt) in 2 dogs and meclofenamate 10 mg/kg in I dog.
These inhibitors were given at the end of a 4- to 6- hr
experiment. RBF decreased 10 to 80 mllmin in these
3 anesthetized and acutely operated animals. Renal
venous PGE2 decreased from 11—100 pg/mi to 3—9
pg/mi, and PGF0 fell from 28—50 pg/mI to 10—15 pgl
ml in the 3 dogs. Arterial BP did not change.
Urine prostaglandins. In 5 anesthetized dogs, we
catheterized the ureter of the instrumented kidney.
In the basal or control state, the urine concentrations
of POE2, PGF0, and DHKF were 1610 350, 1330
150 and 1270 260 pg/mi (mean SEM; N = 9),
respectively. The urine concentrations expressed in
clearances of creatinine were 1710 360, 1510
250, and 1070 180 pg/g for PGE2, PGF12 and
DHKF, respectively. Collection periods ranged from
30 mm to 60 mm. In 2 experiments in which basal
secretory rates (veno-arterial differences) and excre-
tory rates of prostaglandins were simultaneously
measured, the values were roughly comparable in pg/
kidney/mm for PGE2 secretory and excretory rates
(340—480 and 200—480 pg/kidney/mm) and for PGF0
secretory and excretory rates (480—1430 and 370—
6 10). Table 4 summarizes the changes of urine pros-
taglandins after bradykinin infusion. It is apparent
that urine concentrations of PGE2 and PGF0
increased markedly, whereas concentrations of
DHKF0 doubled. In a single experiment with renal
C0
u00.
400
20r1
1*
(10) III(3)
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Table 4. Urine prostaglandins after bradykinin (pg of prostaglandin/g of creatininer
PGE2 PGFa DHKFa
Control BradykininControl5 Bradykininc Control Bradykinin
Dog 20
Dog 21
Dog 23
2920
625
1770
69000
12600
9900
3670
1010
1200
26000
9500
4600
310
1170
1600
710
2110
3630
a Urine was collected from the ipsilateral ureter.
b Mean value of 2 or 3 determinations.
Peak value obtained during a 15 mm infusion of bradykinin (2sgImin) into the ipsilateral renal artery.
arterial infusion of angiotensin 11(100 ng/min), the
urine concentrations of PGE2 and PGFc, increased
fourfold above control values, and DHKFa excretion
doubled.
Discussion
Basal renal secretory or synthetic rates of prosta-
glandins have been quantified infrequently in the
kidney by simultaneous determinations of RBF and
veno-arterial differences of PGE2 and/or PGF2a.
Most investigators have utilized the superfused
organ bioassay, which despite its advantages, lacks
the sensitivity of radioimmunoassay. Hence, this
bioassay method has been unable to detect arterial
levels [5] and, in some instances, nonstimulated or
control renal venous levels [6, 9], despite concentra-
tion and extraction of large volumes of blood. More
recently, there have been several reports of renal
venous concentrations of "PGE" and "PGF" mea-
surable by bioassay in dogs after laparotomy [5, 25].
Our data show that arterial (aortic) concentrations of
PGEZ and PGF are approximately one half the
venous concentrations and, hence, may not be negli-
gible when calculating actual secretory rates; it is
probable, however, that most of the prostaglandin in
arterial blood is metabolized by the kidney. Our
values for basal arterial and renal venous PGE2
(Table 1) are lower than previously reported by the
other investigators who used either bioassay or
radioimmunoassay [5, 24, 25]. The measured values
for renal venous PGF are also lower than previously
reported [5], and no investigators have published
data on arterial PGF. Our data for renal venous
concentrations of PGE2 and PGFc, agree most closely
with recently published bioassay values for unanes-
thetized chronically instrumented dogs: "PGE" =
0.05 0.01 ng/ml, and "PGF" = 0.07 0.02 ng/ml
[5]. We conclude that the measurement of basal
renal veno-arterial differences of PGE2 and PGF2
requires a sensitive assay, precautions to avoid
platelet release of prostaglandins in the catheters or
syringes, and minimal surgical trauma [181, especial-
ly the avoidance of laparotomy [51.
The calculated secretory rates of PGE2 and PGF,
were low, and in some instances no veno-arterial
differences existed. These observations agree with
the conclusions reached by others that basal renal
prostaglandin synthesis may be very small. These
latter conclusions have been based upon the failure
of indomethacin to reduce RBF in the conscious,
unanesthetized dog or baboon [5, 26—28]. Further-
more, Terragno, Terragno, and McGiff [5] have
recently shown that laparatomy increases by seven-
fold the renal venous levels of PGE; anesthesia had
no effect. The retroperitoneal flank approach to the
kidney appears to be less traumatic and appears to be
associated with smaller changes of RBF after inhibi-
tion of PG synthetase [24]. Since we administered
indomethacin or meclofenamate very late in three
experiments (4 to 6 hr after initiating surgery), the
observed reductions of 10 to 80 mllmin in RBF over-
estimate the contribution of prostaglandins in the
maintenance of basal RBF.
Our measurements of renal secretory rates for
PGE2 and PGFa underestimate the actual renal syn-
thetic rate. Since the renal parenchyma contains
prostaglandin degradative enzymes, much of the
prostaglandin produced intracellularly in the renal
medulla is metabolized before appearing in renal
venous blood [1, 2]. As demonstrated in our experi-
ments and in other studies [4, 29, 30], prostaglandins
and their metabolites also are excreted in the urine,
further complicating the use of renal veno-arterial
differences of PGE2 and PGFa for accurately mea-
suring total renal synthesis. Also, most of the arterial
prostaglandins entering the kidney are metabolized,
and hence our use of veno-arterial differences would
underestimate actual renal production. We did
observe, however, reproducible changes of renal
veno-arterial differences of PGE2 and PGF, after
administration of bradykinin, and angiotensin II, and
after renal ischemia; therefore, we believe that renal
veno-arterial differences do reflect synthetic rates.
In general, we observed parallel stimulation of the
secretory rates of both PGE2 and PGF. after ischem-
ia, angiotensin II or bradykinin infusions. This, how-
ever, was not uniformly true, since PGE2 secretion
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increased earlier after renal arterial constriction, and
PGF secretion remained elevated for a longer time
after angiotensin II infusion. The meaning of these
variations is not clear. These increments of renal
venous POE2 are in accord with previously published
experiments of renal arterial constriction [6], angio-
tensin II infusion [8—10], and bradykinin infusion
[13, 14, 16]. We also confirmed the observation of
McGiff et al [8], that the extent of renal vasocon-
striction after angiotensin was inversely related to
the increment of POE2 secretion. Furthermore, the
partial recovery of RBF after arterial constriction
was correlated with the increase of renal PGE2 pro-
duction. In previous reports, renal venous PGF2
was either not measured [18, 24] or was observed to
remain unchanged after stimuli [6, 8, 10, 13]. Isak-
son, Raz, and Needleman [30], using an isolated and
perfused rabbit kidney preparation, found no incre-
ment of PGF2 production despite increases of PGE2
after administration of angiotensin II and bradykinin.
These differences in results are puzzling and may be
related to the study of different species, problems
related to isolated and perfused organs, and differ-
ences in methods of assay. Our data are most consis-
tent with the conclusion that ischemia, angiotensin
and bradykinin act by releasing arachidonic acid
from tissue stores (phospholipids and triglycerides)
as substrate for the general synthesis of prostaglan-
dins. This interpretation is in accord with recently
accumulated data which show that angiotensin II and
bradykinin stimulate prostaglandin synthesis in
diverse systems (cell cultures, perfused heart and
perfused kidneys or renal slices) by enhancing de-
acylation of cellular phospholipids, thereby provid-
ing greater amounts of arachidonic acid for the cyclo-
oxygenase (prostaglandin synthetase) [30—33]. In
unpublished experiments using a radiochemical
assay for prostaglandin synthetase [34], we have also
shown that angiotensin II (1 to 1,000 nglml) and
bradykinin (1 to 1,000 ng/ml) have no stimulatory
effect on rat or rabbit renal medullary microsomal
prostaglandin synthetase assayed in vitro. Dog kid-
ney has very low levels of PGE-9-ketoreductase in
comparison to six other studied species [35]. This
enzyme converts PGE2 to PGF2. Therefore, the
parellel increases of both PGF2, and PGEZ in our
experiments, especially after bradykinin infusion,
favor but do not prove the direct synthesis of PGF2,
from endoperoxides rather than from PGE2 via the
ketoreductase pathway [20].
Determination of urinary prostaglandins and pros-
taglandin metabolites has been recently shown to be
a practical and accurate method of assessing in vivo
prostaglandin changes [4, 19, 30]. Samuelsson et a!
[20] have stated that measurement of prostaglandin
metabolites provides a more accurate indication of in
vivo changes since the metabolites are more stable
biologically and are unaffected by platelet damage.
We found no advantages in measuring the urine con-
centration of DHKF, which is a major metabolite of
PGF2, over the direct measurement of PGE2 and
PGF used in our studies. Although DHKF did
increase in the urine after intrarenal infusion of
bradykinin, the magnitude of the increase was less
than for PGFa or FGE2 (see Table 4). We could not
find a veno-arterial difference for DHKFI, across the
canine kidney, which may indicate that this metabo-
lite is primarily excreted into the urine.
It is interesting that basal renal secretory rates of
PGF, were three times greater than that of PGE2
(Table 1), whereas basal renal excretory rates of
PGFa and PGE2 were comparable. The significance
of this observation is unknown, but may be related to
different rates of tubular secretion and reabsorption
of these prostaglandins from the tubular lumen. Our
data are insufficient to indicate the exact quantitative
relationship between renal secretory rates (veno-
arterial differences) and renal excretory rates (urine
measurements) of the prostaglandins. Our results do
show, however, that stimulation of renal prostaglan-
din production by infusion of bradykinin or angioten-
sin II does substantially increase excretion of PGE2,
PGF, and DHKFa in the urine. Measurement of
urinary prostaglandins offers advantages over the
determination of veno-arterial differences, namely,
ease of collection, absence of platelets, leukocytes,
and erythrocytes—all of which can affect the con-
centrations of plasma prostaglandin and an integrat-
ed estimation, rather than a momentary estimation,
of renal synthetic rates over time.
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